Vladan Vucinic

Featured in: Favicon

nature.com Favicon

wiley.com

onlinelibrary.wiley.com

Articles

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma - Bone Marrow Transplantation

Dec 4, 2024 | nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more

AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT |

Oct 24, 2024 | nature.com | Ana Alarcon Tomas |Edouard Forcade |Vladan Vucinic |Nicolaus Kröger |Lucía López Corral |Jan Vydra | +10 more

Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma - Leukemia

Jan 6, 2024 | nature.com | Anne Sophie Kubasch |Song Wang |Sebastian Schwind |Klaus H. Metzeler |Madlen Jentzsch |Kristin Reiche | +2 more

AbstractB-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited.
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation | Leukemia

Oct 25, 2023 | nature.com | Klaus H. Metzeler |Georg-Nikolaus Franke |Vladan Vucinic |Uwe Platzbecker

To the Editor:Some of the gene mutations detected during the development of myeloid neoplasm are also frequently found in elderly individuals without diagnosed hematologic malignancy and here referred to as clonal hematopoiesis (CH) of indeterminate potential (CHIP) [1]. CHIP associates with an elevated risk of developing a myeloid neoplasm [1], as compared to non-CHIP conductors [1].
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Aug 7, 2023 | onlinelibrary.wiley.com | Luise Fischer |Nora Grieb |Uwe Platzbecker |Vladan Vucinic

5 EMERGING SPECIFIC SIDE EFFECTS BEYOND CRS AND ICANS As described above, BCMA-targeting CAR T cell therapies are accompanied by cytokine release syndrome (CRS) with very diverse degree of severity, ranging from mild flu-like symptoms up to life-threatening cytokine storm reactions. However, in the vast majority, CRS is manageable with supportive care, steroid treatment, tocilizumab, or other cytokine inhibitors.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Vladan Vucinic

Articles

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma - Bone Marrow Transplantation

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT |

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma - Leukemia

Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation | Leukemia

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Contact details

Emails

Socials & Sites